Skip to main content
Equibles
DH logo

DH · Definitive Healthcare Corp. · Metrics

Track DH — free

Use DH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.08 +0.00 (+0.00%) At close · Oct 23
Rebalance outlook locked
Market Cap
$115.28M
Shares
106.74M
Volume · Oct 23 175.61K Avg daily vol (3M) 602.64K

DH metrics

92 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.08
Market cap
$115.28M

Price action

20 metrics
Price change (1W)
+8.0%
Price change (30D)
+6.9%
Price change (3M)
+58.1%
Price change (6M)
+5.9%
Price change (YTD)
-62.4%
Price change (1Y)
-63.4%
Trailing year
Price change (5Y)
-97.2%
52-week high
$2.97
52-week low
$0.63
Change from 52-week high
-63.6%
Change from 52-week low
+72.0%
Annualized volatility
76.9%
Annualized volatility (3M)
74.7%
Beta
1.2
RSI (14D)
61.5
Price vs SMA 50
+15.5%
Price vs SMA 200
-3.0%
Avg volume (3M)
602,636
Relative volume
0.3
Average dollar volume
$572,249

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
106.74M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.4×
reciprocal yield 252.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.5×
reciprocal yield 201.9%
P / book
0.6
reciprocal yield 163.0%
FCF yield
24.8%
TTM · current market cap
Buyback yield
8.0%
P / FCF
4.0
reciprocal yield 24.8%
P / operating cash flow
2.8
reciprocal yield 35.9%
Earnings yield
-104.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.9×
reciprocal yield 52.8%
EV / revenue historical average (5Y)
3.7×
reciprocal yield 27.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
8.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
75.2%
Operating margin
-104.6%
Trailing 12 months
Net margin
-51.7%
Gross profit (TTM)
$175.09M
Operating profit (TTM)
−$243.35M
Net income (TTM)
−$120.33M
Trailing 12 months
Diluted EPS (TTM)
$-1.65
FCF margin
12.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.23
Gross profit per diluted share (TTM)
$1.68
Operating profit per diluted share (TTM)
$-2.33
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.15
Operating cash flow per diluted share (TTM)
$0.40
Free cash flow per diluted share (TTM)
$0.27
Capital expenditures per diluted share (TTM)
$0.12
R&D per diluted share (TTM)
$0.30
Stock compensation per diluted share (TTM)
$0.24
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-9.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$232.70M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-0.9%
Year over year · fewer shares
Revenue CAGR (3Y)
+2.7%
Revenue CAGR (5Y)
+15.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+10.8%
FCF CAGR (5Y)
+11.2%

Quality

14 metrics
Return on equity
-64.1%
Return on assets
-24.2%
Debt / equity
0.9
Current ratio
1.9
EBITDA (TTM)
−$239.44M
Free cash flow (TTM)
$28.56M
Quick ratio
1.9
Interest coverage
-21.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$22.96M
Latest balance sheet
Cash & equivalents
$170.87M
Total assets
$496.83M
Total debt
$160.63M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$41.43M
Capital expenditures (TTM)
$12.87M
R&D (TTM)
$30.76M
SG&A (TTM)
—
Stock compensation (TTM)
$25.32M
R&D / revenue
13.2%
Stock compensation / revenue
10.9%

Ownership (13F)

9 metrics
13F filers
99
13F filer change QoQ
-20
Institutional ownership
81.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
10.0%
Private-fund adviser ownership
7.9%
Active holders' share change QoQ
+2.2%
Holder tenure
17.5
Price vs estimated holder cost
-78.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.4%

Short interest

3 metrics
Short interest
1.6%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1861795 CUSIP 24477E103 13F (30d) 15 filings 15 filers Visit website Investor relations